Company’s 36-month beta value is 0.69.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VTGN is 26.11M, and currently, short sellers hold a 2.04% ratio of that floaft. The average trading volume of VTGN on June 19, 2025 was 135.64K shares.
VTGN) stock’s latest price update
The stock of Vistagen Therapeutics Inc (NASDAQ: VTGN) has decreased by -13.45 when compared to last closing price of 2.38.Despite this, the company has seen a loss of -12.71% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-17 that Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson – VP & Chief Financial Officer Mark Adrian McPartland – Senior Vice President of Investor Relations Shawn K. Singh – President, CEO & Director Conference Call Participants Julian Pino – Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsai – Jefferies LLC, Research Division Myles Robert Minter – William Blair & Company L.L.C.
VTGN’s Market Performance
Vistagen Therapeutics Inc (VTGN) has seen a -12.71% fall in stock performance for the week, with a -19.06% decline in the past month and a -24.26% plunge in the past quarter. The volatility ratio for the week is 8.94%, and the volatility levels for the past 30 days are at 4.46% for VTGN. The simple moving average for the past 20 days is -13.64% for VTGN’s stock, with a -24.11% simple moving average for the past 200 days.
Analysts’ Opinion of VTGN
Many brokerage firms have already submitted their reports for VTGN stocks, with Jefferies repeating the rating for VTGN by listing it as a “Buy.” The predicted price for VTGN in the upcoming period, according to Jefferies is $15 based on the research report published on December 07, 2023 of the previous year 2023.
Maxim Group, on the other hand, stated in their research note that they expect to see VTGN reach a price target of $30. The rating they have provided for VTGN stocks is “Buy” according to the report published on August 07th, 2023.
VTGN Trading at -10.57% from the 50-Day Moving Average
After a stumble in the market that brought VTGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.07% of loss for the given period.
Stock Fundamentals for VTGN
Current profitability levels for the company are sitting at:
- -75.67 for the present operating margin
- 0.77 for the gross margin
The net margin for Vistagen Therapeutics Inc stands at -67.74. The total capital return value is set at -0.64. Equity return is now at value -46.28, with -42.35 for asset returns.
Based on Vistagen Therapeutics Inc (VTGN), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -22.9.
Currently, EBITDA for the company is -32.45 million with net debt to EBITDA at 1.39. When we switch over and look at the enterprise to sales, we see a ratio of -19.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.35.
Conclusion
In a nutshell, Vistagen Therapeutics Inc (VTGN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
